Standard BioTools Return on Equity

Standard BioTools (LAB) currently reports a ROE of 23.95%. That is above the Healthcare sector average of -75.84%. Use the charts on this page to explore Standard BioTools's ROE history and peer comparisons.

Standard BioTools's ROE of 23.95% is higher than the Healthcare sector average of -75.84%. That is roughly 131.6% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Standard BioTools's current 23.95% should be judged against Healthcare norms (sector average: -75.84%) and against LAB's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 23.95%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is -75.84%. From there, open related valuation or income-statement pages for Standard BioTools, and consider following LAB for alerts when major investors trade the stock.

Standard BioTools is classified in the Healthcare sector. On ROE, it currently shows 23.95% versus a sector average near -75.84%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing LAB with unrelated industries.